Lipid lowering for prevention of venous thromboembolism: a network meta-analysis

医学 以兹提米比 他汀类 内科学 荟萃分析 随机对照试验 置信区间 安慰剂 相对风险 瑞舒伐他汀 病理 替代医学
作者
Ioannis T. Farmakis,Konstantinos Christodoulou,Lukas Hobohm,Stavros Konstantinides,Luca Valerio
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:45 (35): 3219-3227 被引量:11
标识
DOI:10.1093/eurheartj/ehae361
摘要

Abstract Background and Aims Studies have suggested that statins may be associated with reduced risk of venous thromboembolism (VTE). The aim of the current study was to assess the evidence regarding the comparative effect of all lipid-lowering therapies (LLT) in primary VTE prevention. Methods After a systematic search of PubMed, CENTRAL, and Web of Science up until 2 November 2022, randomized controlled trials (RCT) of statins (high- or low-/moderate-intensity), ezetimibe, or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) were selected. An additive component network meta-analysis to compare VTE risk during long-term follow-up across different combinations of LLT was performed. Results Forty-five RCTs (n = 254 933 patients) were identified, reporting a total of 2084 VTE events. Compared with placebo, the combination of PCSK9i with high-intensity statin was associated with the largest reduction in VTE risk (risk ratio [RR] 0.59; 95% confidence interval [CI] 0.43–0.80), while there was a trend towards reduction for high-intensity (0.84; 0.70–1.02) and low-/moderate-intensity (0.89; 0.79–1.00) statin monotherapy. Ezetimibe monotherapy did not affect the VTE risk (1.04; 0.83–1.30). There was a gradual increase in the summary effect of VTE reduction with increasing intensity of the LLT. When compared with low-/moderate-intensity statin monotherapy, the combination of PCSK9i and high-intensity statin was significantly more likely to reduce VTE risk (0.66; 0.49–0.89). Conclusions The present meta-analysis of RCTs suggests that LLT may have a potential for VTE prevention, particularly in high-intensity dosing and in combination therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Jasper应助捞鱼采纳,获得10
1秒前
Cat完成签到,获得积分0
2秒前
8R60d8应助潇洒的白昼采纳,获得10
2秒前
2秒前
yx完成签到,获得积分10
2秒前
万能图书馆应助动人的cc采纳,获得10
3秒前
3秒前
Malmever发布了新的文献求助20
3秒前
4秒前
今后应助ererrrr采纳,获得10
4秒前
肉肉发布了新的文献求助10
5秒前
稀罕你发布了新的文献求助10
5秒前
心心长点心完成签到,获得积分10
6秒前
叶永芬完成签到,获得积分10
6秒前
yx完成签到,获得积分10
6秒前
Janvenns完成签到,获得积分10
7秒前
情怀应助ayuelei采纳,获得30
7秒前
彭于晏应助西西采纳,获得30
7秒前
赘婿应助o30采纳,获得10
8秒前
Steven完成签到,获得积分10
8秒前
8秒前
yx发布了新的文献求助10
9秒前
LIUUU完成签到,获得积分10
10秒前
旷野发布了新的文献求助10
10秒前
时空路人完成签到,获得积分10
10秒前
11秒前
寒冷书竹发布了新的文献求助10
11秒前
科研通AI2S应助貔貅采纳,获得10
11秒前
Yesyes完成签到,获得积分10
11秒前
SciGPT应助落后的哈密瓜采纳,获得10
12秒前
mia完成签到,获得积分10
13秒前
晾猫人发布了新的文献求助10
14秒前
小树枝完成签到,获得积分20
14秒前
欣慰墨镜发布了新的文献求助10
15秒前
qq完成签到,获得积分20
15秒前
Malmever完成签到,获得积分10
15秒前
gwff发布了新的文献求助10
15秒前
彭于晏应助稀罕你采纳,获得10
15秒前
共享精神应助肉肉采纳,获得10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969458
求助须知:如何正确求助?哪些是违规求助? 3514286
关于积分的说明 11173363
捐赠科研通 3249652
什么是DOI,文献DOI怎么找? 1794948
邀请新用户注册赠送积分活动 875501
科研通“疑难数据库(出版商)”最低求助积分说明 804836